NCT03798678 2026-03-17
CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
Clinical Trials
36 trialsNCT05552976 2026-03-17
SUCCESSOR-2
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT04883242 2026-03-13
Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
University of Washington
Phase 2 Active not recruiting
NCT05050097 2026-03-13
MonumenTAL-2
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT05434689 2026-03-05
COMMANDER
University of Alabama at Birmingham
Phase 1/2 Active not recruiting
NCT03729804 2026-03-04
(COBRA)
University of Chicago
Phase 3 Active not recruiting
NCT04933539 2026-02-27
Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT04764942 2026-02-25
Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial
Mayo Clinic
Phase 1/2 Active not recruiting
NCT01297764 2026-02-19
QUAD
Hackensack Meridian Health
Phase 1/2 Active not recruiting
NCT05572515 2026-02-13
MajesTEC-9
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT04113018 2026-02-03
Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
Wake Forest University Health Sciences
Phase 2 Active not recruiting
NCT05497804 2026-02-03
Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial
Mayo Clinic
Phase 2 Active not recruiting
NCT04430894 2026-01-29
KRDI in Transplant-Eligible MM
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT05704049 2025-12-29
IZALCO
Sanofi
Phase 2 Active not recruiting
NCT04850599 2025-12-18
Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT03290950 2025-12-15
A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03500445 2025-10-03
Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma
University of Chicago
Phase 2 Active not recruiting
NCT03004287 2025-09-10
2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
University of Arkansas
Phase 2 Active not recruiting
NCT01559935 2025-09-08
CarBiRD
Weill Medical College of Cornell University
Phase 2 Active not recruiting
NCT01863550 2025-09-08
Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Eastern Cooperative Oncology Group
Phase 3 Active not recruiting
NCT02899052 2025-08-05
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
AbbVie
Phase 2 Active not recruiting
NCT04458831 2025-06-27
IONA-MM
Sanofi
Active not recruiting
NCT01816971 2025-06-10
Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
University of Chicago
Phase 2 Active not recruiting
NCT02332850 2025-05-01
Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma
University of California, San Francisco
Phase 1 Active not recruiting
NCT03556332 2025-04-29
A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT05669989 2025-01-23
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
Sanofi
Phase 2 Active not recruiting
NCT04096066 2025-01-15
KRdvsRd
Fondazione EMN Italy Onlus
Phase 3 Active not recruiting
NCT02203643 2024-12-05
FORTE
University of Turin, Italy
Phase 2 Active not recruiting
NCT03989414 2024-11-29
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
Celgene
Phase 1/2 Active not recruiting
NCT04934475 2024-11-07
MIDAS
Intergroupe Francophone du Myelome
Phase 3 Active not recruiting
NCT04756401 2024-09-26
Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma
Academic and Community Cancer Research United
Phase 2 Active not recruiting
NCT02773030 2024-06-25
A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma
Celgene
Phase 1/2 Active not recruiting
NCT03104842 2024-05-29
Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone
Universitätsklinikum Hamburg-Eppendorf
Phase 2 Active not recruiting
NCT03948035 2023-05-06
Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM
Wuerzburg University Hospital
Phase 3 Active not recruiting
NCT03651128 2022-12-15
KarMMa-3
Celgene
Phase 3 Active not recruiting
NCT03606577 2021-04-28
IFM 2018-04
Nantes University Hospital
Phase 2 Active not recruiting